Evidence map›Paper›PMID 23713819›Full record

ArticleBritish journal of pharmacology2013

A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia.

Bopanna I Kalappa, Fen Sun, Stephen R Johnson, Kunlin Jin, Victor V Uteshev

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Modulation of CaScientific reports · 2024
    Article
  4. Therapeutic effect ofJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  5. Article
  6. Therapeutic Targeting ofPharmacological reviews · 2021
    Review
  7. Changing Functional Signatures of Microglia along the Axis of Brain Aging.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Bopanna I KalappaDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Fen Sun
Stephen R Johnson
Kunlin Jin
Victor V Uteshev
University of North Texas · USIR Dynamics (United States) · USSouthern Illinois University School of Medicine · USUniversity of North Texas Health Science Center · US

Funding

Responsiveness to nicotine of nucleus tractus solitarius neuronsR01DK082625 · NIDDK · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI UTESHEV, VICTOR V · 2009 to 2013
$1.7M
NIDDK NIH HHS DK-082625NIDDK NIH HHS R01 DK082625
6 · The paper itself

Abstract

background and purposeActivation of α7 nicotinic acetylcholine receptors (nAChRs) can be neuroprotective. However, endogenous choline and ACh have not been regarded as potent neuroprotective agents because physiological levels of choline/ACh do not produce neuroprotective levels of α7 activation. This limitation may be overcome by the use of type-II positive allosteric modulators (PAMs-II) of α7 nAChRs, such as 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea (PNU-120596). This proof-of-concept study presents a novel neuroprotective paradigm that converts endogenous choline/ACh into potent neuroprotective agents in cerebral ischaemia by inhibiting α7 nAChR desensitization using PNU-120596. EXPERIMENTAL APPROACH: An electrophysiological ex vivo cell injury assay (to quantify the susceptibility of hippocampal neurons to acute injury by complete oxygen and glucose deprivation; COGD) and an in vivo middle cerebral artery occlusion model of ischaemia were used in rats. KEY

resultsCholine (20-200 μM) in the presence, but not absence of 1 μM PNU-120596 significantly delayed anoxic depolarization/injury of hippocampal CA1 pyramidal neurons, but not CA1 stratum radiatum interneurons, subjected to COGD in acute hippocampal slices and these effects were blocked by 20 nM methyllycaconitine, a selective α7 antagonist, thus, activation of α7 nAChRs was required. PNU-120596 alone was ineffective ex vivo. In in vivo experiments, both pre- and post-ischaemia treatments with PNU-120596 (30 mg·kg(-1) , s.c. and 1 mg·kg(-1) , i.v., respectively) significantly reduced the cortical/subcortical infarct volume caused by transient focal cerebral ischaemia. PNU-120596 (1 mg·kg(-1) , i.v., 30 min post-ischaemia) remained neuroprotective in rats subjected to a choline-deficient diet for 14 days prior to experiments. CONCLUSIONS AND IMPLICATIONS: PNU-120596 and possibly other PAMs-II significantly improved neuronal survival in cerebral ischaemia by augmenting neuroprotective effects of endogenous choline/ACh.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorAnimalsBrain IschemiaCholineHippocampusIn Vitro TechniquesIsoxazolesMaleNeuronsNeuroprotective AgentsNicotinic AgonistsPatch-Clamp TechniquesPhenylurea CompoundsRatsRats, Sprague-Dawley1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)ureaalpha7 Nicotinic Acetylcholine ReceptorCholineIsoxazolesNeuroprotective AgentsNicotinic AgonistsPhenylurea Compoundsanoxic depolarizationcholinecortexhippocampusischaemianeuroprotectionPNU-120596PNU120596α7 nAChR

Identifiers

PMID23713819
PMCPMC3753841
OpenAlexW1690463461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.